MetaCap

Mustang Bio (MBIO) vs Redhill Biopharma (RDHL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Mustang Bio is the larger company by market cap ($2.7 million vs $2.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MBIO-21.35%RDHL-40.72%
+25%-9%-44%
Oct 7, 20261 yearNov 20, 2026
MBIO-11.50%RDHL-47.87%
+8%-21%-51%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MBIO versus RDHL key metrics
MetricMBIORDHL
Share price$0.3541$0.281
Market cap$2.69M$2.50M
1-day change-4.30%-13.08%
Forward P/E—9.37
EPS (TTM)$-0.51$0.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$8.04M
Revenue growth (YoY)—+23.17%
Net income (latest FY)$-1.92M$-8.27M
Gross margin—60.31%
Operating margin—-181.69%
Net margin—-102.80%
52-week high$1.43$1.60
52-week low$0.35$0.281
Distance from 52-week high-75.24%-82.44%
Average volume33.87K2.08M
Shares outstanding6.74M8.89M
Employees413
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Mustang Bio

MBIO stock →

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Redhill Biopharma

RDHL stock →

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

MBIO vs RDHL FAQ

Which is bigger, Mustang Bio or Redhill Biopharma?

Mustang Bio (MBIO) is larger, with a market capitalization of $2.69M compared with $2.50M for Redhill Biopharma (RDHL).

Are Mustang Bio and Redhill Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons